Small PrEP RCT showing that PrEP with HCQ is safe at the dosage used. There were no deaths, hospitalizations, or serious adverse events.
The paper states: "Among all trial participants at the end of the first month (n=253), only one participant from the placebo arm (1/116, 0.8%), tested positive for SARS-CoV-2 PCR and for a SARS-CoV-2 serology test".
The abstract states: "only one participant in each group was diagnosed with COVID-19".
Grau-Pujol et al., 21 Sep 2020, Randomized Controlled Trial, Spain, peer-reviewed, 22 authors.